PTHS — Pelthos Therapeutics Share Price
Last trade - 00:00- $63.76m
- $66.01m
- 16
- 25
- 74
- 31
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.2 | n/a | n/a | n/a | n/a | 5.64 | 26.56 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Channel Therapeutics Corporation is engaged in developing innovative, non-addictive, drugs to treat chronic neuropathic and acute and chronic eye pain. The Company is focused on the development of non-opioid pain treatment therapeutics with a focus on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system. It is initially targeting orphan chronic pain indications, specifically small fiber neuropathy and erythromelalgia, and acute and chronic eye pain. The Company’s patented, selective, and potent (nM) inhibitor of human NaV1.7 has demonstrated additional efficacy in several models of pain: acute, chronic, inflammatory, visceral, post-surgical, and chemotherapy-induced.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- November 5th, 2024
- Public Since
- February 16th, 2024
- No. of Shareholders
- 16
- No. of Employees
- 4
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 3,042,143
- Address
- 4020 Stirrup Creek Drive, Suite 110, DURHAM, 27703
- Web
- https://ir.pelthos.com/
- Phone
- +1 9199082422
- Auditors
- Marcum LLP
Upcoming Events for PTHS
Similar to PTHS
Can Fite Biopharma
NYSE MKT
cbdMD
NYSE MKT
China Pharma Holdings
NYSE MKT
Nasus Pharma
NYSE MKT
NovaBay Pharmaceuticals
NYSE MKT
FAQ
As of Today at 22:35 UTC, shares in Pelthos Therapeutics are trading at $20.96. This share price information is delayed by 15 minutes.
Shares in Pelthos Therapeutics last closed at $20.96 and the price had moved by +160.37% over the past 365 days. In terms of relative price strength the Pelthos Therapeutics share price has outperformed the S&P500 Index by +124.22% over the past year.
The overall consensus recommendation for Pelthos Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePelthos Therapeutics does not currently pay a dividend.
Pelthos Therapeutics does not currently pay a dividend.
Pelthos Therapeutics does not currently pay a dividend.
To buy shares in Pelthos Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $20.96, shares in Pelthos Therapeutics had a market capitalisation of $63.76m.
Here are the trading details for Pelthos Therapeutics:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: PTHS
Based on an overall assessment of its quality, value and momentum Pelthos Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Pelthos Therapeutics is $60.00. That is 186.26% above the last closing price of $20.96.
Analysts covering Pelthos Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.55 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pelthos Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +5.95%.
As of the last closing price of $20.96, shares in Pelthos Therapeutics were trading +53.43% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pelthos Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $20.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Pelthos Therapeutics' directors